Molecule Details
| InChIKey | PFGVNLZDWRZPJW-OPAMFIHVSA-N |
|---|---|
| Compound Name | Otamixaban |
| Canonical SMILES | COC(=O)[C@H](Cc1cccc(C(=N)N)c1)[C@@H](C)NC(=O)c1ccc(-c2cc[n+]([O-])cc2)cc1 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 3 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 7.29 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB06635 |
|---|---|
| Drug Name | Otamixaban |
| CAS Number | 193153-04-7 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Otamixaban is a novel direct Factor Xa (FXa) inhibitor. It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome. |
Categories: Anticoagulants Antithrombins Enzyme Inhibitors Factor Xa Inhibitors Hematologic Agents Protease Inhibitors Serine Protease Inhibitors
Cross-references: BindingDB: 50114539 CHEMBL46618 ChemSpider: 4593439 PubChem:5496659 Wikipedia: Otamixaban ZINC: ZINC000001908051
Target Activities (3)
DrugBank Target Actions (1)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| P00742 | F10 | Coagulation factor X | inhibitor | targets |